Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage

References

• Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalysed by human cytochrome P450 enzymes: A comparison with SKF-525A and ketoconazole. Drug Metabolism and Pharmacokinetics 2003; 18: 287–295
   PubMedGoogle Scholar
• Emoto C, Murase S, Sawada Y, Iwasaki K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: A comparison with SKF-525A. Drug Metabolism and Pharmacokinetics 2005; 20: 351–357
   PubMedGoogle Scholar
• Huang W, Lin YS, McConn DJ, II, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metabolism and Disposition 2004; 32: 1434–1445
   PubMed Web of Science ®Google Scholar
• Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Therapeutic Drug Monitoring 1998; 20: 243–247
   PubMed Web of Science ®Google Scholar
• Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics Concepts 1994; 26: 144–160
   PubMed Web of Science ®Google Scholar
• Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Archives of Biochemistry and Biophysics 1998; 353: 16–28
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Parker AJ, Soars M, Riley RJ. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition 2000; 28: 1327–1334
   PubMed Web of Science ®Google Scholar
• Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPs. Drug Metabolism and Disposition 1999; 27: 1381–1391
   PubMed Web of Science ®Google Scholar
• Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, Yokoi T. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: Effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. Journal of Pharmaceutical Sciences 2002; 91: 952–963
   PubMed Web of Science ®Google Scholar
• Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics 1985; 38: 402–408
   PubMed Web of Science ®Google Scholar
• Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
   PubMedGoogle Scholar
• Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and non-specific binding to microsomes. Drug Metabolism and Disposition 1999; 27: 1350–1359
   PubMed Web of Science ®Google Scholar
• Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metabolism and Disposition 2002; 30: 831–837
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology 1999; 57: 465–480
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Current Drug Metabolism 2002; 3: 289–309
   PubMed Web of Science ®Google Scholar
• Soars MG, Gelboin HV, Krausz KW, Riley RJ. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. British Journal of Clinical Pharmacology 2003; 55: 175–181
   PubMed Web of Science ®Google Scholar
• Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 1995; 27: 397–417
   PubMed Web of Science ®Google Scholar
• Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metabolism and Disposition 2005; 33: 1723–1728
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, Von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, Shader RI, Greenblatt DJ. Relative contribution of CYP3A to amitriptyline clearance in humans: In vitro and in vivo studies. Journal of Clinical Pharmacology 2001; 41: 1043–1054
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metabolism and Disposition 2000; 28: 1493–1504
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. Journal of Pharmaceutical Sciences 1998; 87: 845–853
   PubMed Web of Science ®Google Scholar
• Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita K, Kamataki T. Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: Similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochemical Pharmacology 2003; 66: 2333–2340
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 434–442
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, Yokoi T. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b5 in bacterial membranes. Drug Metabolism and Disposition 1999; 27: 999–1004
   PubMed Web of Science ®Google Scholar